Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS Genomics
Dyadic International, Inc. (DYAI)
NASDAQ:AMEX Investor Relations:
dyadic.com
Company Research
Source: GlobeNewswire
JUPITER, Fla. and DUBLIN, Nov. 10, 2025 (GLOBE NEWSWIRE) -- ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today announced a CRISPR/Cas9 license agreement. This agreement grants Dyadic access to ERS’ CRISPR/Cas9 patent portfolio, enhancing Dyadic’s ability to accelerate strain engineering and pathway optimization to enhance productivity, product quality, and innovation across its proprietary bioproduction platforms. “Access to ERS Genomics’ foundational CRISPR/Cas9 patent portfolio expands our genetic engineering toolkit and strengthens our ability to speed up and optimize strain development across Dyadic’s proprietary C1 and Dapibus production platforms,” stated Joe Hazelton, President and COO, Dyadic Applied BioSolutions. “This agreement supports both Dyadic’s internal product pipeline and the customized
Show less
Read more
Impact Snapshot
Event Time:
DYAI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DYAI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DYAI alerts
High impacting Dyadic International, Inc. news events
Weekly update
A roundup of the hottest topics
DYAI
News
- Dyadic International (NASDAQ:DYAI) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Dyadic and BRIG BIO Sign Development & Commercialization Agreement to Bring Animal-Free Bovine Alpha-Lactalbumin to Global Nutrition MarketsGlobeNewswire
- Dyadic International, Inc. (DYAI) Q3 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic ProgressGlobeNewswire
- Dyadic International Inc (DYAI) Q3 2025 Earnings Report Preview: What To Expect [Yahoo! Finance]Yahoo! Finance
DYAI
Earnings
- 11/12/25 - Miss
DYAI
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/12/25 - Form 8-K
- 11/12/25 - Form 10-Q
- DYAI's page on the SEC website